A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer
- PMID: 20545611
- DOI: 10.2174/138945010792006780
A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer
Abstract
Aberrant activation of the Wnt/beta-catenin signaling pathway is a hallmark of many tumors, including breast cancer. In the normal breast, tightly regulated expression of Wnt/beta-catenin pathway components, including Wnts and the APC tumor suppressor, dictates its role in balancing stem cell self-renewal, maintenance and differentiation during embryonic and postnatal development. Therefore, not surprisingly, dysregulation of Wnt/beta-catenin signaling through overexpression of pathway activators, such as Wnts or stabilized beta-catenin, or targeted disruption of inhibitors, such as APC, leads to mammary tumorigenesis in several genetically engineered mouse (GEM) models. These models are powerful tools to dissect the importance of Wnt/beta-catenin signaling in human breast cancer because they recapitulate some of the histological features of human breast cancers that demonstrate pathway dysregulation. Over the last decade, numerous approaches have been developed to target the Wnt/beta-catenin pathway in tumor cells, from antagonizing Wnt ligand secretion or binding to promoting beta-catenin degradation to specifically blocking beta-catenin-mediated transcriptional activity. Despite sizeable hurdles because of gaps in our knowledge of most efficacious ways to inhibit the pathway, the breast cancer subtypes to target and how pathway antagonists might be used in combination therapy, crippling Wnt/beta-catenin signaling offers a tremendous opportunity to impact breast cancer pathogenesis. This review will provide an overview of the current understanding of Wnt/beta-catenin pathway involvement in regulating normal breast development and morphogenesis, the generation of Wnt/beta-catenin-dependent GEM models of human breast cancer, upregulation of signaling in human breast cancers and the compelling therapeutic strategies aimed at targeting the Wnt/beta-catenin pathway that show promising anti-tumor activity.
Similar articles
-
Redundant expression of canonical Wnt ligands in human breast cancer cell lines.Oncol Rep. 2006 Mar;15(3):701-7. Oncol Rep. 2006. PMID: 16465433
-
GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity.Oncogene. 2019 Jun;38(26):5294-5307. doi: 10.1038/s41388-019-0793-7. Epub 2019 Mar 26. Oncogene. 2019. PMID: 30914799
-
MicroRNA-1229 overexpression promotes cell proliferation and tumorigenicity and activates Wnt/β-catenin signaling in breast cancer.Oncotarget. 2016 Apr 26;7(17):24076-87. doi: 10.18632/oncotarget.8119. Oncotarget. 2016. PMID: 26992223 Free PMC article.
-
Role of regulatory miRNAs of the Wnt/ β-catenin signaling pathway in tumorigenesis of breast cancer.Gene. 2020 Sep 5;754:144892. doi: 10.1016/j.gene.2020.144892. Epub 2020 Jun 10. Gene. 2020. PMID: 32534060 Review.
-
FAK and WNT signaling: the meeting of two pathways in cancer and development.Anticancer Agents Med Chem. 2011 Sep;11(7):600-6. doi: 10.2174/187152011796817673. Anticancer Agents Med Chem. 2011. PMID: 21707509 Review.
Cited by
-
Molecular targeted therapies for cutaneous squamous cell carcinoma: recent developments and clinical implications.EXCLI J. 2024 Feb 27;23:300-334. doi: 10.17179/excli2023-6489. eCollection 2024. EXCLI J. 2024. PMID: 38655092 Free PMC article. Review.
-
Nimbolide: promising agent for prevention and treatment of chronic diseases (recent update).Food Nutr Res. 2024 Mar 18;68. doi: 10.29219/fnr.v68.9650. eCollection 2024. Food Nutr Res. 2024. PMID: 38571915 Free PMC article.
-
Zebrafish drug screening identifies Erlotinib as an inhibitor of Wnt/β-catenin signaling and self-renewal in T-cell acute lymphoblastic leukemia.Biomed Pharmacother. 2024 Jan;170:116013. doi: 10.1016/j.biopha.2023.116013. Epub 2023 Dec 16. Biomed Pharmacother. 2024. PMID: 38104416 Free PMC article.
-
β-catenin inhibitors in cancer therapeutics: intricacies and way forward.Bioengineered. 2023 Dec;14(1):2251696. doi: 10.1080/21655979.2023.2251696. Bioengineered. 2023. PMID: 37655825 Free PMC article. Review.
-
The landscape of exosomal non-coding RNAs in breast cancer drug resistance, focusing on underlying molecular mechanisms.Front Pharmacol. 2023 Apr 19;14:1152672. doi: 10.3389/fphar.2023.1152672. eCollection 2023. Front Pharmacol. 2023. PMID: 37153758 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials